This combined therapy can improve the tumor microenvironment, increasing sensitivity to immune checkpoint inhibitors, promoting cyt c induced tumor cell death and significantly enhancing the therapeutic effect on HER2-positive breast cancer [68]. This evidence concerns the gene ERBB2 and breast carcinoma.